Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial

医学 利西塞纳泰德 微量白蛋白尿 安慰剂 肾功能 蛋白尿 内科学 肌酐 2型糖尿病 糖尿病 艾塞那肽 随机对照试验 急性冠脉综合征 临床终点 泌尿科 心肌梗塞 内分泌学 病理 替代医学
作者
Marcel H.A. Muskiet,Lennart Tonneijck,Yao‐Kuang Huang,Minzhi Liu,Aramesh Saremi,Hiddo J.L. Heerspink,Daniël H. van Raalte
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:6 (11): 859-869 被引量:254
标识
DOI:10.1016/s2213-8587(18)30268-7
摘要

Background The results of the ELIXA trial demonstrated the cardiovascular safety of lixisenatide, a short-acting glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes and acute coronary syndrome. In this exploratory analysis of ELIXA, we investigate the effect of lixisenatide on renal outcomes. Methods ELIXA was a randomised, double-blind, placebo-controlled trial, done at 828 sites in 49 countries. Patients with type 2 diabetes and a recent coronary artery event were randomly assigned (1:1) to a daily subcutaneous injection of lixisenatide (10–20 μg) or volume-matched placebo, in addition to usual care, until at least 844 patients had an adjudicated major adverse cardiovascular event included in the primary outcome. Patients, study staff, and individuals involved in analysis of trial data were masked to treatment assignment. The primary and secondary endpoints of this trial have been reported previously. Here, in an exploratory analysis of ELIXA, we investigated percentage change in urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) according to prespecified albuminuria status at baseline (normoalbuminuria [UACR <30 mg/g]; microalbuminuria [≥30 to ≤300 mg/g]; and macroalbuminuria [>300 mg/g]) using a mixed-effect model with repeated measures. Time to new-onset macroalbuminuria and doubling of serum creatinine were also assessed with Cox proportional hazards models. The ELIXA trial is registered with ClinicalTrials.gov, number NCT01147250, and is completed. Findings Of 6068 patients randomly allocated between July 9, 2010, and Aug 2, 2013, baseline UACR data were available for 5978 (99%). Median follow-up time was 108 weeks. 4441 (74%; 2191 assigned to placebo and 2250 assigned to lixisenatide) had normoalbuminuria, 1148 (19%; 596 assigned to placebo and 552 assigned to lixisenatide) had microalbuminuria, and 389 (7%; 207 assigned to placebo and 182 assigned to lixisenatide) had macroalbuminuria. After 108 weeks, the placebo-adjusted least-squares mean percentage change in UACR from baseline with lixisenatide was −1·69% (95% CI −11·69 to 8·30; p=0·7398) in patients with normoalbuminuria, −21·10% (−42·25 to 0·04; p=0·0502) in patients with microalbuminuria, and −39·18% (−68·53 to −9·84; p=0·0070) in patients with macroalbuminuria. Lixisenatide was associated with a reduced risk of new-onset macroalbuminuria compared with placebo when adjusted for baseline HbA1c (hazard ratio [HR] 0·808 [95% CI 0·660 to 0·991; p=0·0404]) or baseline and on-trial HbA1c (HR 0·815 [0·665 to 0·999; p=0·0491]); point estimates were similar when adjusted for other traditional renal risk factors. At week 108, the largest eGFR decline from baseline was observed in the macroalbuminuric group, but no significant differences were observed between the two treatment groups. No significant differences in eGFR decline were identified between treatment groups in any UACR subgroup. In the trial safety population, doubling of serum creatinine occurred in 35 (1%) of 3032 patients in the placebo group and 41 (1%) of 3031 patients in the lixisenatide group (HR 1·163, 95% CI 0·741–1·825; p=0·5127). As previously reported in the ELIXA trial, the proportion of patients with renal adverse events was low (48 [1·6%] of 3032 patients in the placebo group vs 48 [1·6%] of 3031 patients in the lixisenatide group) and did not significantly differ between treatment groups. Interpretation Lixisenatide reduces progression of UACR in macroalbuminuric patients, and is associated with a lower risk of new-onset macroalbuminuria after adjustment for baseline and on-trial HbA1c and other traditional renal risk factors. Funding Sanofi.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
不爱吃早饭完成签到 ,获得积分10
刚刚
刚刚
烟花的应助被深林狼采纳,获得100
刚刚
科目三的应助被1101592875采纳,获得30
刚刚
YananLi完成签到,获得积分10
刚刚
沉淀发布了新的文献求助10
1秒前
1秒前
Lizhiiiy完成签到,获得积分10
1秒前
时长两年半完成签到,获得积分10
1秒前
无花果的应助被发嗲的乘云采纳,获得10
1秒前
1秒前
Septvirouo9完成签到,获得积分10
1秒前
俊俊发布了新的文献求助10
2秒前
2秒前
香蕉寒珊完成签到,获得积分10
2秒前
AAA095完成签到,获得积分10
2秒前
zhaoxixi发布了新的文献求助20
2秒前
3秒前
3秒前
3秒前
山石梦沧海完成签到,获得积分10
3秒前
英俊的铭的应助被风月将晚采纳,获得10
4秒前
终梦的应助被Vivi采纳,获得10
4秒前
hua发布了新的文献求助10
4秒前
SciGPT的应助被专注秋尽采纳,获得10
5秒前
小巧的洋葱完成签到,获得积分10
5秒前
Solitary发布了新的文献求助10
5秒前
英俊的铭的应助被张博采纳,获得10
5秒前
物理循州发布了新的文献求助10
6秒前
清水17完成签到 ,获得积分10
6秒前
6秒前
汉堡包的应助被lily采纳,获得10
6秒前
syr111完成签到,获得积分10
6秒前
1900发布了新的文献求助10
7秒前
空空发布了新的文献求助10
7秒前
嘟嘟嘟嘟完成签到,获得积分10
7秒前
李爱国的应助被大力的安青采纳,获得20
7秒前
沉默怜容发布了新的文献求助10
7秒前
Aaron完成签到,获得积分10
8秒前
小金发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181072
求助须知:如何正确求助?哪些是违规求助? 9571092
关于积分的说明 21816478
捐赠科研通 7777477
什么是DOI,文献DOI怎么找? 3433418
关于科研通互助平台的介绍 2557638
邀请新用户注册赠送积分活动 2479460